Cargando…
Cetrorelix in reproductive medicine
This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201282/ https://www.ncbi.nlm.nih.gov/pubmed/37223762 http://dx.doi.org/10.1016/j.xfre.2022.11.012 |
_version_ | 1785045233508024320 |
---|---|
author | Findeklee, Sebastian Diedrich, Prof Klaus |
author_facet | Findeklee, Sebastian Diedrich, Prof Klaus |
author_sort | Findeklee, Sebastian |
collection | PubMed |
description | This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol |
format | Online Article Text |
id | pubmed-10201282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102012822023-05-23 Cetrorelix in reproductive medicine Findeklee, Sebastian Diedrich, Prof Klaus F S Rep Special Issue This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol Elsevier 2022-11-21 /pmc/articles/PMC10201282/ /pubmed/37223762 http://dx.doi.org/10.1016/j.xfre.2022.11.012 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Special Issue Findeklee, Sebastian Diedrich, Prof Klaus Cetrorelix in reproductive medicine |
title | Cetrorelix in reproductive medicine |
title_full | Cetrorelix in reproductive medicine |
title_fullStr | Cetrorelix in reproductive medicine |
title_full_unstemmed | Cetrorelix in reproductive medicine |
title_short | Cetrorelix in reproductive medicine |
title_sort | cetrorelix in reproductive medicine |
topic | Special Issue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201282/ https://www.ncbi.nlm.nih.gov/pubmed/37223762 http://dx.doi.org/10.1016/j.xfre.2022.11.012 |
work_keys_str_mv | AT findekleesebastian cetrorelixinreproductivemedicine AT diedrichprofklaus cetrorelixinreproductivemedicine |